Product Information
RHOFADE 1% CREAM is a brand product labeled by Mayne Pharma, priced at $23.4743 per GM under NDC 51862076530. Its NADAC has been published 86 times since Feb 12, 2025.
FDA first approved this application on Jan 18, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the oxymetazoline hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
10 mg/g
Manufacturer
Mayne PharmaNDC
51862076530
Classification
Brand
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
OXYMETAZOLINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA208552FDA Approved
1/18/2017
TE Code
AB
On Market Since
10/24/2024
Pharmacological Classes
Price Statistics
The NADAC for RHOFADE 1% CREAM has been published 86 times since Feb 12, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $23.4743 per GM |
|---|---|
| All-time high | $23.4862 (Dec 10, 2025) |
| All-time low | $21.9772 (Jul 23, 2025) |
| 52-week high | $23.4862 |
| 52-week low | $22.3808 |
| Median price | $23.4652 |
| Average price | $23.2296 |
| Largest weekly change | -6.4% (Jul 23, 2025) |
| Weeks tracked | 86 |
| Tracking since | Feb 12, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the oxymetazoline hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mayne Pharma manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
oxymetazoline hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Vasoconstrictor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RHOFADE 1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for RHOFADE 1% CREAM, manufactured by Mayne Pharma, is $23.4743 per GM (NDC 51862076530), effective Sep 30, 2026.
How has the price of RHOFADE 1% CREAM changed over time?
Over the history we have for it, the NADAC for RHOFADE 1% CREAM has held within roughly two percent of its current level. It has been tracked across 86 weekly CMS publications since Feb 12, 2025.
What are the highest and lowest recorded NADAC prices for RHOFADE 1% CREAM?
Since Feb 12, 2025, the NADAC for RHOFADE 1% CREAM has ranged from a low of $21.9772 (Jul 23, 2025) to a high of $23.4862 (Dec 10, 2025), with a median of $23.4652 per GM.
Are there cheaper alternatives to RHOFADE 1% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of RHOFADE 1% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RHOFADE 1% CREAM?
RHOFADE 1% CREAM (NDC 51862076530) is labeled by Mayne Pharma, and CMS classifies it as a brand product.